Updates on pancreas exocrine function in cystic fibrosis for the era of highly effective modulator therapy
Journal of Cystic Fibrosis · 2026-05 · 25 (3) · 437-442
DOI: 10.1016/j.jcf.2026.03.018 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cystic Fibrosis, 2026-05. Verfasst von Mitchell L Ramsey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Ele…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Enzyme Replacement Therapy, Exocrine Pancreatic Insufficiency, Pancreas, Exocrine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
The pancreas is one of the earliest affected organs in cystic fibrosis (CF). Most newborn screening programs are based on pancreatic inflammation causing elevated trypsinogen at birth, and most individuals with CF are born with exocrine pancreatic insufficiency (PI) which requires lifelong treatment with pancreas enzyme replacement therapy (PERT). However, as CFTR modulating therapies (CFTRm) are administered earlier and earlier, these paradigms may be changing. In this article, we summarize updates on the diagnosis and treatment of exocrine pancreatic disease in CF in the era of CFTRm. We provide a concise review on the natural history of the exocrine pancreas in CF as a context to discuss new observations of CFTRm use at different time points in utero, in childhood, and in adulthood. Clinicians are encouraged to obtain objective exocrine function testing (i.e., fecal elastase) among individuals receiving CFTRm therapy, and to counsel patients and/or parents on the unknowns regarding natural history during CFTRm use. Few patients will regain pancreatic sufficiency (PS) and we encourage clinicians to de-escalate PERT stepwise, rather than discontinue abruptly. Lastly, it is important to note that most reports of improved exocrine function are described in children, and individuals who started CFTRm in adulthood are unlikely to experience reduction in PERT dose and should continue close monitoring for late complications of severe PI, like fat soluble vitamin deficiency and metabolic bone disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Hepatology, and Nutrition, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: Mitchell.Ramsey@osumc.edu.
- School of Clinical Medicine, Discipline of Paediatrics & Child Health, Randwick Clinical Campus, Faculty of Medicine & Health, University of New South Wales, Sydney, Australia; Department of Gastroenterology, Sydney Chi…
Förderung
- Cystic Fibrosis Foundation
- National Health and Medical Research Council
Zitieren
APA
Ramsey, M. L., & Ooi, C. Y. (2026). Updates on pancreas exocrine function in cystic fibrosis for the era of highly effective modulator therapy. Journal of Cystic Fibrosis, 25(3), 437-442. https://doi.org/10.1016/j.jcf.2026.03.018
Vancouver
Ramsey ML, Ooi CY. Updates on pancreas exocrine function in cystic fibrosis for the era of highly effective modulator therapy. Journal of Cystic Fibrosis. 2026;25(3):437-442. doi:10.1016/j.jcf.2026.03.018
BibTeX
@article{Ramsey2026,
author = {Ramsey, Mitchell L and Ooi, Chee Y},
title = {Updates on pancreas exocrine function in cystic fibrosis for the era of highly effective modulator therapy},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {3},
pages = {437--442},
doi = {10.1016/j.jcf.2026.03.018}
}
EUVIMED